key: cord-0784848-xnaqpo0v authors: Alpert, Naomi; Rapp, Joseph L; Marcellino, Bridget; Lieberman-Cribbin, Wil; Flores, Raja; Taioli, Emanuela title: Clinical Course of Cancer Patients with COVID-19: A Retrospective Cohort Study date: 2020-11-02 journal: JNCI Cancer Spectr DOI: 10.1093/jncics/pkaa085 sha: bab17b996b30493101cf2b87e137b86fdd85cf6d doc_id: 784848 cord_uid: xnaqpo0v BACKGROUND: Complications in cancer patients with COVID-19 have not been examined. This analysis aimed to compare characteristics of COVID-19 patients with and without cancer, and assess whether cancer is associated with COVID-19 morbidity or mortality. METHODS: COVID-19 positive patients with an inpatient or emergency encounter at the Mount Sinai Health System between March 1, 2020 and May 27, 2020 were included, and compared across cancer status on demographics and clinical characteristics. Multivariable logistic regressions were used to model the associations of cancer with sepsis, venous thromboembolism, acute kidney injury, intensive care unit admission, and all-cause mortality. RESULTS: There were 5,556 COVID-19 positive patients included; 421 (7.6%) with cancer (325 solid, 96 non-solid). Those with cancer were statistically significantly older, more likely to be non-Hispanic Black and to be admitted to the hospital during their encounter, and had more comorbidities than non-cancer COVID-19 patients. Cancer patients were statistically significantly more likely to develop sepsis (adjusted odds ratio [OR(adj)]=1.31, 95% confidence interval [CI]=1.06-1.61) and venous thromboembolism (OR(adj)=1.77, 95% CI = 1.01-3.09); there was no statistically significant difference in acute kidney injury (OR(adj)=1.10, 95% CI = 0.87-1.39), intensive care unit admissions (OR(adj)=1.04, 95% CI = 0.80-1.34), or mortality (OR(adj)=1.02, 95% CI = 0.81-1.29). CONCLUSIONS: COVID-19 patients with cancer may have a higher risk for adverse outcomes. Although there was no statistically significant difference in mortality, COVID-19 patients with cancer have significantly higher risk of thromboembolism and sepsis. Further research is warranted into the potential effects of cancer treatments on inflammatory and immune responses to COVID-19, and on the efficacy of anticoagulant therapy in these patients. The coronavirus disease-2019 pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged at the end of 2019(1) resulting in millions of people infected and over 770,000 deaths worldwide, as of August 18 th , 2020. ( 2) The SARS-CoV-2 infection is associated with a wide array of pulmonary, cardiovascular and neurological complications (3, 4) and has been shown to stimulate a "cytokine storm", which results in an uncontrolled systemic inflammatory response that can affect many organs. (5) There is an urgent need to understand the risk factors associated with COVID-19 morbidity and mortality in order to accurately predict which patients will need the most aggressive care. Initial studies identified patients with chronic pulmonary and cardiovascular diseases, and diabetes at particularly high risk of severe COVID-19 disease. (6) (7) (8) (9) It is currently unclear, however, whether active cancer confers an increased risk of morbidity and mortality in COVID-19 patients. Cancer patients are particularly vulnerable, as they may be immunosuppressed due to the cancer itself or as a consequence of cancer treatment. (10) Additionally, cancer is generally considered a hypercoaguable state, (11, 12) and the finding that SARS-CoV-2 infection is associated with thrombotic complications (13) has raised concerns that cancer patients with COVID-19 could be particularly at risk of thrombotic events. To date research on COVID-19 in cancer patients has largely focused on how this infection impacts cancer care. The pandemic has clearly led to interruptions in cancer patients' care, including altered chemotherapy schedules, delays in scheduled curative surgery, and inaccessibility to clinical trials. (14) (15) (16) The few studies which have assessed risks that cancer patients with COVID-19 face involve a relatively small subset of patients, are largely focused on hematologic malignancies, (17) and have provided conflicting data. While there is some evidence that COVID-19 patients with cancer, particularly those with hematological malignancies, have 5 higher mortality risk, (17, 18) other studies have found no increased risk of intubation or mortality in cancer patients. (19) Additionally, it is unclear what role cancer therapies play in altering the response to the COVID-19 infection. We analyzed a large registry based dataset to compare the demographic and clinical characteristics of COVID-19 patients with and without an active cancer to determine whether an active cancer diagnosis was an independent risk factor for adverse outcomes. We used anonymous data from the Mount Sinai Health System (MSHS) COVID-19 registry, which includes all patients with an encounter at a MSHS facility who were diagnosed with, under investigation, or screened for COVID-19. This research on a de-identified dataset was deemed exempt by the Mount Sinai Institutional Review Board (IRB# 20-03334, FWA #00005656). Patient encounters from March 1, 2020 to May 27, 2020 were considered (n=61,081). COVID-19 positive patients with blood work performed were selected (n=6144). To exclude asymptomatic cancer patients who had COVID-19 tests during encounters unrelated to COVID-19, and to identify patients who were likely to have data on clinical outcomes, only those with an inpatient or emergency encounter (n=5,637) were included in this analysis. The first such record for each patient was selected. Newborns and women who were at the hospital for labor and delivery were excluded (n=81), resulting in a final sample of 5,556 patients ( Figure 1 ). Patients were identified as having cancer if they had any ICD-10-CM code starting with "C" that was listed as "Active" in their medical record. This included patients with a newly diagnosed cancer or those on an active course of treatment, but not those with a history of 6 cancer. Leukemia, lymphoma, and myeloma were classified as non-solid tumors. Additional comorbidities, including asthma, chronic obstructive pulmonary disease (COPD), hypertension, obesity, diabetes, chronic kidney disease, heart failure, atrial fibrillation, liver disease, and coronary artery disease were also defined if they were active in the patient's medical record. Labs of interest included blood cell counts, serum creatinine, C-reactive protein (CRP), fibrinogen, D-dimer, ferritin, partial thromboplastin time (PTT), prothrombin time, TNF-alpha, interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-1 beta (IL-1β). Outcomes of interest included acute kidney injury, venous thromboembolism (VTE), sepsis (as defined by Bone et al. (20) ), all-cause mortality, and among those with an inpatient encounter, admissions to the Intensive Care Unit (ICU). Cancer and non-cancer patients were compared on baseline demographics, comorbidities, and outcomes using χ 2 and t-tests for categorical and continuous variables. Laboratory values were compared using linear regression for continuous values and logistic regression for categorical variables, adjusted for age, sex, and number of comorbidities. Lab value observations outside 3 standard deviations of the mean were excluded (range nexcluded=2 for IL-8 (0.2% of available observations) to 148 for serum creatinine (2.7%)). Univariate and multivariable logistic regressions were conducted to assess the associations of cancer with outcomes. Multivariable analyses were adjusted for age, sex, and number of additional comorbidities, and stratified into solid and non-solid cancers. Outcomes were also assessed using a 1:2 optimal propensity score(21) matched analysis (maximum difference=0.001), matching on age, sex, and number of comorbidities. All tests of statistical significance were two-sided at α=.05. A Bonferroni-Holm correction for multiple comparisons was applied to p-values of outcomes analyses. Analyses were conducted in SAS, version 9.4 (SAS Institute, Cary, NC). There were 5,556 patients who met the selection criteria, of which 421 (7.6%) had cancer (325 solid tumors, 96 non-solid tumors) ( Table 1) . Those with cancer were statistically significantly older, more likely to be non-Hispanic Black, and more likely to be admitted to the hospital than non-cancer patients. Those with cancer were statistically significantly more likely to have additional comorbidities and were more frequently obese. Those without cancer had statistically significantly worse O2 saturation than cancer patients (Table 1) . Patients with solid cancers were statistically significantly older (mean=70.9 vs. 63.2 years, p<.001), more likely to be non-Hispanic Black (26.5% vs 22.9%, p=.005), and more likely to be admitted to the hospital (88.3% vs. 83.3%, p=.03) than non-solid cancer patients. After adjusting for age, sex, and number of comorbidities, patients with cancer had statistically significantly lower levels of platelets, hemoglobin, red blood cells, and white blood cells than those without cancer. Mean counts of white blood cell subpopulations, including lymphocytes, monocytes, and neutrophils were statistically significantly lower in cancer patients. Although not significant, cancer patients tended to have lower basophil count and percent ( Table 2 ). 8 Serum creatinine and fibrinogen were statistically significantly higher in non-cancer patients than in cancer patients. While not significant, cancer patients tended to have lower CRP than non-cancer patients ( Table 2) . When cancer patients were stratified into solid and non-solid cancers, those with nonsolid cancers had lower mean platelet count (184.1 vs 222.6 x10 3 /μL; p<.001), hemoglobin (11. vs. 12.1 g/dL; p<.001), red blood cell count (3.7 vs 4.2 x10 6 /μL; p<.001) and white blood cell count (6.8 vs. 7.9 x10 3 /μL; p<.001) than those with solid cancer. Mean lymphocyte count was statistically significantly lower in the solid cancer group (mean=0.98, vs 1.04 x10 3 /μL in nonsolid cancer; p=.01), while mean monocyte counts (non-solid=0.47 vs. solid=0.53 x10 3 /μL; p=.02) and neutrophil counts (non-solid=5.3 vs. solid=6.3 x10 3 /μL; p<.001) were statistically significantly lower in the non-solid cancer group Those with non-solid cancer had a higher percentage of lymphocytes (mean= 16.2%, vs 13.7%; p=.05) and a lower percentage of neutrophils (mean=71.7% vs. 77.3%; p<.001), compared to solid-cancer patients. Though not statistically significant, those with non-solid cancers also tended to have lower basophil counts. Ferritin was statistically significantly higher in non-solid cancer patients (mean=1613.2 vs. 1040.9 ng/mL; p=.006) than in solid-cancer patients, as was fibrinogen (mean non-solid= 599.9 vs. solid=584.6 mg/dL; p=0.01). Patients with cancer were more likely to develop VTE, and were statistically significantly more likely to have acute kidney injury, sepsis, and to be deceased than those without cancer. Among those with an inpatient encounter, there was no statistically significant difference in ICU admissions between cancer and non-cancer patients (Table 1 ). 9 After adjusting for age, sex, and the number of additional comorbid conditions, those with cancer were statistically significantly more likely to develop sepsis (ORadj=1. 31 After propensity matching, the cancer and non-cancer groups were well balanced on age, sex, and number of comorbidities (ncancer=420, nnon-cancer=840). Results were consistent with the multivariable analysis with increased odds of VTE and sepsis, and no statistically significant difference in acute kidney injury, all-cause mortality, or ICU admission (Table 3) . Among cancer patients, those with neutropenia (neutrophil count <1000/μL) had statistically significantly higher rates of sepsis than those without neutropenia (92.3% vs. 59.2%, p=.02), and slightly, though not statistically significant, higher rates of mortality (38.5% vs. 30 .5%, p=.55). There was a non-statistically significant inverse association between platelet number and VTE in cancer patients (mean platelet=184.8 vs. 223.3 x10 3 /μL in those with and without VTE, p=.23). Among patients with sepsis, cancer patients had non-statistically significant higher mortality rates (34.0% vs. 29.9%, p=.18). This analysis of more than 5,000 patients hospitalized for COVID-19 in New York City patients. 12 Despite differences in sepsis and VTE risks between cancer and non-cancer patients, there was no difference in mortality between the two groups. Our findings are contrasted by other studies that found that cancer was predictive of mortality in COVID-19 patients, including a meta-analysis which included data from eight nations. (36) However, this meta-analysis reports crude estimates, and did not adjust the analysis for age, which is known to be a major predictor of COVID-19 outcomes and is associated with cancer. Additionally, many of the included studies had few cancer patients, limiting generalizability. The study by Kuderer et al. also indicated that patients with active cancer had higher mortality risk from COVID-19. (22) However, this study included all subjects with COVID-19 from Vanderbilt University Medical Center's data registry, and compared to patients in recovery phase. Our study was limited to emergency room or inpatient encounters, thus including cases with a clinical symptomatology that required hospital attention. It is possible that cancer patients in the general population are more likely to develop a serious infection from SARS-CoV-2, as suggested by others. (22, 24, 36) However, our research suggests that once an infection has progressed to a stage that requires hospitalization, cancer's role in increased short-term mortality risk is more limited. The present analysis also indicates that there are no statistically significant differences in all-cause mortality between solid and non-solid tumors. This is important, given that non-solid cancers place patients at higher risk for developing sepsis and VTEs. Our results agree with Kuderer's results, which also found no significant difference in mortality by tumor type. (22) This dataset also allowed us to look at inflammatory response parameters; we found no statistically significant difference between cancer and non-cancer patients in terms of cytokine response, highlighting that cytokine storm does not appear to be more of a concern for cancer patients than non-cancer patients. This is clinically relevant as it can set expectations for future 13 cancer patients admitted with SARS-CoV-2. To our knowledge, this is the first observation of this kind in cancer patients. Additionally, laboratory tests indicate statistically significant differences in white blood cells response in favor of non-cancer patients, even after adjusting for clinical and demographic differences; this could be due to a variety of factors, including the disease itself, cancer therapies, or a dampened immune response. (37) The role that prior therapy plays in outcomes is not sufficiently clear, as one study of cancer patients indicated no significant difference in mortality, by receipt of chemotherapy. (38) Although we were unable to explore this more in detail, as the dataset contains no information on treatments prior to the COVID-19-related encounter, this is important information to consider moving forward. Results should be interpreted within the possibility of chance finding and in the context of the data limitations. We used a retrospective registry, and therefore we were unable to acquire information on previous treatments or the timing of a patient's cancer diagnosis, which could have aided in better understanding the complications observed. As all patients included were required to have either emergency or inpatient care, this analysis does not address whether cancer patients are more likely to contract COVID-19 or to need hospital care if they do. Because cancer patients typically have more contact with health care systems, (39) it is possible that some cancer patients were diagnosed with COVID-19 during an encounter related to cancer care, but not to a COVID-19 clinical manifestation. However, we minimized this effect by excluding patients with routine encounters for laboratory work, or outpatient or nurse's office visits. It is possible that not all patients completed their clinical course before data collection, and remained at risk of developing adverse outcomes. As this dataset is hospital-based, it is also difficult to assess outcomes that occurred after discharge. While this means that we may 14 undercount the number of adverse outcomes, we believe this is unlikely to have biased the results, as we do not expect the distributions of those who had not completed the clinical course or developed outcomes after discharge to differ by cancer status. We don't know how representative the COVID-19 population served by MSHS is of all NYC residents, but previous health assessments show that MSHS patients are very diverse in race, socio-economic status, and insurance. During the COVID pandemic, New York State required all hospitals to enter an agreement to share patients in order to provide care to all as hospitals were being overwhelmed. (40) Due to these guidelines, we think it is likely that the MSHS may have served an even more representative NYC population. This study adds to the knowledge of risks to patients with a dual COVID-19 and cancer diagnosis. To our knowledge, this is the largest study on COVID-19 cancer patients that includes comprehensive information on comorbidities, laboratory values, and outcomes, including VTE and sepsis. As follow up of COVID-19 patients is limited, it is too soon to tell whether there are increased long-term risks of morbidity and mortality for patients with a concurrent cancer. Future research would benefit from a registry coding structure for COVID-19 cancer patients, (41) and should include treatment information for these patients, and longer follow up to address and respond to chronic effects of COVID-19 infection on cancer patients. Clinical Characteristics of Coronavirus Disease World Health Organization. WHO Coronavirus (COVID-19) Dashboard Neurological manifestations and complications of COVID-19: A literature review Cardiovascular complications in COVID-19. The American journal of emergency medicine The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19) Asthma prolongs intubation in COVID-19. The journal of allergy and clinical immunology In practice Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease Nosocomial infections in patients with cancer The hypercoagulable state of malignancy: pathogenesis and current debate Epidemiology and pathophysiology of cancer-associated thrombosis Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? Acta Haematol Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! Effect of the COVID-19 pandemic on cancer treatment and research Adapting to a Pandemic -Conducting Oncology Trials during the SARS-CoV-2 Pandemic Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis Annals of oncology : official journal of the European Society for Medical Oncology Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis A General SAS Macro to Implement Optimal N:1 Propensity Score Matching Within A Maximum Radius Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. The Lancet Oncology Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System INFECTIOUS MORBIDITY IN CRITICALLY ILL PATIENTS WITH CANCER The Epidemiology of Sepsis in Patients With Malignancy Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care Critically ill patients with cancer and sepsis: Clinical course and prognostic factors Tissue factor as a tumor procoagulant Cancer-associated thrombosis: an overview Cancer-associated thrombosis. The open cardiovascular medicine journal The MET oncogene drives a genetic programme linking cancer to haemostasis Cancer and venous thromboembolism Epidemiology of cancer-related venous thromboembolism. Best practice & research Clinical haematology Malignancies, prothrombotic mutations, and the risk of venous thrombosis Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis The role of immunity in elderly cancer COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet Healthcare utilisation in general practice and hospitals in the year preceding a diagnosis of cancer recurrence or second primary cancer: a population-based register study Amid Ongoing COVID-19 Pandemic, Governor Cuomo Announces New Hospital Network Central Coordinating Team COVID-19 Data and the Cancer Patient: A Need for Registry Inclusion No new data were generated by the authors of this study.